Announcement

Collapse
No announcement yet.

US FluView - Weekly Surveillance Flu report 2021/2022 season - for trend analysis

Collapse
This is a sticky topic.
X
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report

    Print
    Updated November 18, 2022

    Note: CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review.

    Note: Due to the Thanksgiving holiday, FluView for Week 46 will be posted on November 28, 2022.

    Key Updates for Week 45, ending November 12, 2022

    Seasonal influenza activity is elevated across the country.
    Viruses


    Clinical Lab14.7%


    positive for influenza
    this week


    Public Health Lab
    The most frequently reported viruses this week were influenza A(H3N2).

    Virus Characterization
    Genetic and antigenic characterization are summarized in this report.
    Illness


    Outpatient Respiratory Illness5.8%


    of visits to a health care provider are for respiratory illness this week
    (above baseline)


    Outpatient Respiratory Illness: Activity Map
    This week, 6 jurisdictions experienced moderate activity and 30 jurisdictions experienced high or very high activity.

    Long-term Care Facilities1.2%


    of facilities reported
    ≥ 1 influenza-positive test
    among residents this week.

    Severe Disease


    FluSurv-NET8.1 per 100,000


    cumulative hospitalization rate

    HHS Protect Hospitalizations8,707


    patients admitted to hospitals with influenza
    this week.


    NCHS Mortality9.4%


    of deaths attributed to pneumonia, influenza, or COVID-19 this week (above threshold)

    Pediatric Deaths2


    deaths were reported this week for a total of 7 so far this season.

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

    Key Points
    • Seasonal influenza activity is elevated across the country.
    • The majority of influenza viruses detected this season have been influenza A(H3N2) viruses, but the proportion of subtyped influenza A viruses that are A(H1N1) is increasing slightly.
    • Two more influenza-associated pediatric deaths were reported this week, for a total of seven pediatric flu deaths reported so far this season.
    • CDC estimates that, so far this season, there have been at least 4.4 million illnesses, 38,000 hospitalizations, and 2,100 deaths from flu.
    • The cumulative hospitalization rate in the FluSurv-NET system is higher than the rate observed in week 45 during every previous season since 2010-2011.
    • The majority of influenza viruses tested are in the same genetic subclade as and antigenically similar to the influenza viruses included in this season’s influenza vaccine.
    • An annual flu vaccine is the best way to protect against flu. Vaccination helps prevent infection and can also prevent serious outcomes in people who get vaccinated but still get sick with flu.
    • CDC recommends that everyone ages 6 months and older get a flu vaccine annually. Now is a good time to get vaccinated.
    • There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.
    U.S. Virologic Surveillance


    Nationally, the percentage of specimens testing positive for influenza in clinical laboratories is increasing. Percent positivity increased ≥ 0.5 percentage points this week in regions 1, 2, 3, 5, 7, 8, and 10. The majority of viruses detected so far this season have been influenza A(H3N2), however during the past three week, approximately 26% of the subtyped influenza A viruses have been influenza A(H1N1)pdm09 viruses. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 103,830 575,479
    No. of positive specimens (%) 15,308 (14.7%) 49,726 (8.6%)
    Positive specimens by type
    Influenza A 15,185 (99.2%) 49,064 (98.7%)
    Influenza B 123 (0.8%) 662 (1.3%)

    View Chart Data | View Full Screen
    Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
    No. of specimens tested 7,575 53,659
    No. of positive specimens 912 4,493
    Positive specimens by type/subtype
    Influenza A 911 (99.9%) 4,459 (99.2%)
    (H1N1)pdm09 121 (24.6%) 807 (22.8%)
    H3N2 370 (75.4%) 2,733 (77.2%)
    H3N2v 0 1 (<0.1%)
    Subtyping not performed 420 918
    Influenza B 1 (0.1%) 34 (0.8%)
    Yamagata lineage 0 0
    Victoria lineage 0 18 (100%)
    Lineage not performed 1 16


    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Influenza Virus Characterization


    CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans.

    CDC genetically characterized 589 influenza viruses collected since May 1, 2022.
    A/H1 74
    6B.1A 74 (100%) 5a.1 5 (6.8%)
    5a.2 69 (93.2%)
    A/H3 510
    3C.2a1b 510 (100%) 1a 0
    1b 0
    2a 0
    2a.1 0
    2a.2 510 (100%)
    3C.3a 0 3a 0
    B/Victoria 5
    V1A 5 (100%) V1A 0
    V1A.1 0
    V1A.3 0
    V1A.3a 0
    V1A.3a.1 0
    V1A.3a.2 5 (100%)
    B/Yamagata 0
    Y3 0
    CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2022-2023 Northern Hemisphere recommended egg-based and cell- or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

    Influenza A Viruses
    • A (H1N1)pdm09: Thirty-three A(H1N1)pdm09 viruses were antigenically characterized by HI, and 31 (94%) were well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/588/2019-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines and 31 (94%) were well recognized by ferret antisera to egg-grown A/Victoria/2570/2019-like reference viruses representing the A(H1N1)pdm09 component for the egg-based influenza vaccines.
    • A (H3N2): Fifty A(H3N2) viruses were antigenically characterized by HINT; all were well-recognized (reacting at titers that were within 8-fold of the homologous virus titer) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines and 48 (96%) were well-recognized by ferret antisera to egg-grown A/Darwin/9/2021-like reference viruses representing the A(H3N2) component for egg-based influenza vaccines.

    Influenza B Viruses
    • B/Victoria: One influenza B/Victoria-lineage virus was antigenically characterized by HI; it was well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines and by ferret antisera to egg-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the egg-based influenza vaccines.
    • B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

    CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir. Virus antiviral susceptibility data will be reported later this season when a sufficient number of specimens have been tested.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 45, 5.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This is above the national baseline of 2.5%. All 10 HHS regions are above their respective baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data (current season only) | View Full Screen
    Outpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    The percentage of visits for respiratory illness reported in ILINet is increasing in the 0-4 years, 25-49 years, 50-64 years, and 65+ years age groups, while remaining stable in the 5-24 years age group.



    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 45
    (Week ending
    Nov. 12, 2022)
    Week 44
    (Week ending
    Nov. 5, 2022)
    Week 45
    (Week ending
    Nov. 12, 2022)
    Week 44
    (Week ending
    Nov. 5, 2022)
    Very High 16 16 66 74
    High 14 9 150 132
    Moderate 6 7 101 94
    Low 11 7 139 134
    Minimal 8 16 225 262
    Insufficient Data 0 0 248 233



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 45, 174 (1.2%) of 14,161 reporting LTCFs reported at least one influenza positive test among their residents.


    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 13 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

    A total of 2,370 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2022, and November 12, 2022; 95.6% were associated with influenza A virus, 2.4% were associated with influenza B virus, 0.3% with influenza A virus and influenza B virus co-infection, and 1.6% with influenza virus for which the type was not determined. Among 317 hospitalizations with influenza A subtype information, 23.3% were A(H1N1)pdm09 virus and 76.7% were A(H3N2).

    The overall cumulative hospitalization rate per 100,000 population was 8.1. This cumulative hospitalization rate is higher than the cumulative in-season hospitalization rate observed in week 45 during previous seasons going back to 2010-2011, which ranged from 0.1 to 0.9. The highest hospitalization rates per 100,000 population were among adults aged ≥ 65 years (18.6), followed by children aged 0-4 years (13.6), adults aged 50-64 (8.0), children aged 5-17 years (7.3), and adults aged 18-49 years (4.2).

    Cumulative hospitalization rates for each age group were higher than cumulative in-season hospitalization rates previously observed during week 45; since 2010-11 in-season rates ranged from 0 to 1.6 among children 0-4 years, 0 to 0.5 among children 5-17 years, 0 to 0.4 among adults 18-49 years, 0.1 to 0.9 among adults 50-64 years, and 0.3 to 2.7 among adults ≥ 65 years.



    View Full Screen

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 45, 8,707 patients with laboratory-confirmed influenza were admitted to a hospital.


    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on November 17, 2022, 9.4% of the deaths that occurred during the week ending November 12, 2022 (week 45), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 6.2% for this week. Among the 2,175 PIC deaths reported for this week, 926 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and 70 listed influenza. While current PIC mortality is due primarily to COVID-19, the proportion due to influenza remains small but is increasing. The data presented are preliminary and may change as more data are received and processed.

    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    Two influenza-associated pediatric deaths occurring during the 2022-2023 season were reported to CDC during week 45. One death was associated with an influenza A(H1N1)pdm09 virus and one death was associated with an influenza A(H3) virus. Both deaths occurred during week 44 (the week ending November 5, 2022).

    A total of seven influenza-associated pediatric deaths occurring during the 2022-2023 season have been reported to CDC.

    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report

    Print
    Updated November 10, 2022

    Note: CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review.

    Key Updates for Week 44, ending November 5, 2022

    Early increases in seasonal influenza activity continue nationwide. The southeastern and south-central areas of the country are reporting the highest levels of activity followed by the Mid-Atlantic and the south-central West Coast regions.
    Viruses


    Clinical Lab12.8%


    positive for influenza
    this week


    Public Health Lab
    The most frequently reported viruses this week were influenza A(H3N2).

    Virus Characterization
    Genetic and antigenic characterization are summarized in this report.
    Illness


    Outpatient Respiratory Illness5.5%


    of visits to a health care provider are for respiratory illness this week
    (above baseline)


    Outpatient Respiratory Illness: Activity Map
    This week, 6 jurisdictions experienced moderate activity and 25 jurisdictions experienced high or very high activity.

    Long-term Care Facilities1.0%


    of facilities reported
    ≥ 1 influenza-positive test
    among residents this week.

    Severe Disease


    FluSurv-NET5.0 per 100,000


    cumulative hospitalization rate

    HHS Protect Hospitalizations6,465


    patients admitted to hospitals with influenza
    this week.


    NCHS Mortality9.0%


    of deaths attributed to pneumonia, influenza, or COVID-19 this week (above threshold)

    Pediatric Deaths3


    deaths were reported this week for a total of 5 so far this season.

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

    Key Points
    • Influenza activity continues to increase. Regions 4 (Southeast) and 6 (South-Central) are reporting the highest levels of flu activity, followed by regions 3 (Mid-Atlantic) and 9 (south-central West Coast).
    • Three influenza-associated pediatric deaths were reported this week.
    • CDC estimates that, so far this season, there have been at least 2.8 million illnesses, 23,000 hospitalizations, and 1,300 deaths from flu.
    • The cumulative hospitalization rate in the FluSurv-NET system is higher than the rate observed in week 44 during every previous season since 2010-2011.
    • An annual flu vaccine is the best way to protect against flu. Vaccination helps prevent infection and can also prevent serious outcomes in people who get vaccinated but still get sick with flu.
    • CDC recommends that everyone ages 6 months and older get a flu vaccine annually.
    • There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.
    U.S. Virologic Surveillance


    Nationally, the percentage of specimens testing positive for influenza in clinical laboratories is increasing. Percent positivity increased ≥ 0.5 percentage points this week in all regions. The majority of viruses detected so far this season have been influenza A(H3N2), however approximately 30% of the subtyped influenza A viruses have been influenza A(H1N1) viruses. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 103,311 457,029
    No. of positive specimens (%) 13,178 (12.8%) 32,046 (7.0%)
    Positive specimens by type
    Influenza A 13,086 (99.3%) 31,558 (98.5%)
    Influenza B 92 (0.7%) 488 (1.5%)

    View Chart Data | View Full Screen
    Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
    No. of specimens tested 8,824 44,656
    No. of positive specimens 705 2,854
    Positive specimens by type/subtype
    Influenza A 700 (99.3%) 2,824 (98.9%)
    (H1N1)pdm09 108 (24.9%) 485 (21.2%)
    H3N2 325 (75.1%) 1,798 (78.8%)
    H3N2v 0 0
    Subtyping not performed 267 541
    Influenza B 5 (0.7%) 30 (1.1%)
    Yamagata lineage 0 0
    Victoria lineage 0 15 (100.0%)
    Lineage not performed 5 15


    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Influenza Virus Characterization


    CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

    CDC genetically characterized 490 influenza viruses collected since May 1, 2022.
    A/H1 57
    6B.1A 57 (100%) 5a.1 5 (8.8%)
    5a.2 52 (91.2%)
    A/H3 431
    3C.2a1b 431 (100%) 1a 0
    1b 0
    2a 0
    2a.1 0
    2a.2 431 (100%)
    3C.3a 0 3a 0
    B/Victoria 2
    V1A 2 (100%) V1A 0
    V1A.1 0
    V1A.3 0
    V1A.3a 0
    V1A.3a.1 0
    V1A.3a.2 2 (100%)
    B/Yamagata 0
    Y3 0
    CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2022-2023 Northern Hemisphere recommended egg-based and cell- or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

    Influenza A Viruses
    • A (H1N1)pdm09:Twenty-six A(H1N1)pdm09 viruses were antigenically characterized by HI, and 24 (92%) were well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/588/2019-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines and 24 (92%) were well recognized by ferret antisera to egg-grown A/Victoria/2570/2019-like reference viruses representing the A(H1N1)pdm09 component for the egg-based influenza vaccines.
    • A (H3N2): Forty-two A(H3N2) viruses were antigenically characterized by HINT; all were well-recognized (reacting at titers that were within 8-fold of the homologous virus titer) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines and 40 (95%) were well-recognized by ferret antisera to egg-grown A/Darwin/9/2021-like reference viruses representing the A(H3N2) component for egg-based influenza vaccines.

    Influenza B Viruses
    • B/Victoria: One influenza B/Victoria-lineage virus was antigenically characterized by HI; it was well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines and by ferret antisera to egg-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the egg-based influenza vaccines.
    • B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

    Virus antiviral susceptibility data will be reported later this season when a sufficient number of specimens have been tested.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 44, 5.5% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This is an increase compared to week 43 and is above the national baseline of 2.5%. All ten HHS regions are above their respective baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data (current season only) | View Full Screen
    Outpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    The percentage of visits for respiratory illness reported in ILINet is increasing in all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years, and 65+ years).



    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 44
    (Week ending
    Nov. 5, 2022)
    Week 43
    (Week ending
    Oct. 29, 2022)
    Week 44
    (Week ending
    Nov. 5, 2022)
    Week 43
    (Week ending
    Oct. 29, 2022)
    Very High 16 1 71 9
    High 9 4 132 24
    Moderate 6 4 91 38
    Low 10 12 136 109
    Minimal 14 34 256 507
    Insufficient Data 0 0 243 242



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 44, 141 (1.0%) of 14,225 reporting LTCFs reported at least one influenza positive test among their residents.


    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 13 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

    A total of 1,472 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2022, and November 5, 2022; 96.1% were associated with influenza A virus, 2.7% were associated with influenza B virus, 0.5% with influenza A virus and influenza B virus co-infection, and 0.7% with influenza virus for which the type was not determined. Among 192 hospitalizations with influenza A subtype information, 25.0% were A(H1N1)pdm09 virus and 74.5% were A(H3N2).

    The overall cumulative hospitalization rate per 100,000 population was 5.0. This cumulative hospitalization rate is higher than the cumulative in-season hospitalization rate observed in week 44 during previous seasons going back to 2010-2011, which ranged from 0.1 to 0.7. The highest hospitalization rates per 100,000 population were among adults aged ≥ 65 years (10.7), followed by children aged 0-4 years (9.3), adults aged 50-64 (4.9), children aged 5-17 years (5.0), and adults aged 18-49 years (2.6).

    Cumulative hospitalization rates for each age group were higher than cumulative in-season hospitalization rates previously observed during week 44; since 2010-11, in-season rates ranged from 0 to 1.1 among children 0-4 years, 0 to 0.4 among children 5-17 years, 0 to 0.3 among adults 18-49 years, 0.1 to 0.9 among adults 50-64 years, and 0.2 to 2.3 among adults ≥ 65 years.



    View Full Screen

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 44, 6,465 patients with laboratory-confirmed influenza were admitted to a hospital.


    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on November 10, 2022, 9.0% of the deaths that occurred during the week ending November 5, 2022 (week 44), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 6.1% for this week. Among the 2,135 PIC deaths reported for this week, 949 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and 54 listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.

    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    Three influenza-associated pediatric deaths occurring during the 2022-2023 season were reported to CDC during week 44. The deaths occurred during weeks 41 (the week ending October 15, 2022), 43 (the week ending October 29, 2022), and 44 (the week ending November 5, 2022). All three deaths were associated with influenza A viruses. Two of the influenza A viruses had subtyping performed; one was an A(H1N1)pdm09 virus and one was an A(H3) virus.

    A total of five influenza-associated pediatric deaths occurring during the 2022-2023 season have been reported to CDC.

    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive

    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report

    Print
    Updated November 4, 2022

    Note: CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review.

    Key Updates for Week 43, ending October 29, 2022

    Early increases in seasonal influenza activity continue nationwide. The southeastern and south-central areas of the country are reporting the highest levels of activity followed by the Mid-Atlantic and the south-central West Coast regions.
    Viruses


    Clinical Lab9.0%


    positive for influenza
    this week


    Public Health Lab
    The most frequently reported viruses this week were influenza A(H3N2).

    Virus Characterization
    Genetic and antigenic characterization are summarized in this report.
    Illness


    Outpatient Respiratory Illness4.3%


    of visits to a health care provider are for respiratory illness this week
    (above baseline)


    Outpatient Respiratory Illness: Activity Map
    This week, 4 jurisdictions experienced moderate activity and 19 jurisdictions experienced high or very high activity.

    Long-term Care Facilities0.8%


    of facilities reported
    ≥ 1 influenza-positive test
    among residents this week.

    Severe Disease


    FluSurv-NET2.9 per 100,000


    cumulative hospitalization rate

    HHS Protect Hospitalizations4,326


    patients admitted to hospitals with influenza
    this week.


    NCHS Mortality9.1%


    of deaths attributed to pneumonia, influenza, or COVID-19 this week (above threshold)

    Pediatric Deaths2


    deaths were reported (1 occurred in 2021-22 season and 1 occurred in 2022-23 season).

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

    Key Points
    • Influenza activity continues to increase. Regions 4 (Southeast) and 6 (South-Central) are reporting the highest levels of flu activity, followed by regions 3 (Mid-Atlantic) and 9 (south-central West Coast).
    • One human infection with a novel influenza A virus was reported by the New Mexico Department of Health.
    • The second pediatric death of the 2022-23 influenza season was reported this week.
    • CDC estimates that, so far this season, there have been at least 1,600,000 illnesses, 13,000 hospitalizations, and 730 deaths from flu.
    • The cumulative hospitalization rate in the FluSurv-NET system is higher than the rate observed in week 43 during every previous season since 2010-2011.
    • An annual flu vaccine is the best way to protect against flu. Vaccination helps prevent infection and can also prevent serious outcomes in people who get vaccinated but still get sick with flu.
    • CDC recommends that everyone ages 6 months and older get a flu vaccine annually.
    • There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.
    U.S. Virologic Surveillance


    Nationally, the percentage of specimens testing positive for influenza in clinical laboratories is increasing. Percent positivity increased ≥ 0.5 percentage points this week in all regions. The majority of viruses detected so far this season have been influenza A(H3N2), however the proportion of influenza A(H1N1) viruses is increasing nationally. In Region 5, the majority of viruses detected during week 43 were influenza A(H1N1). For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 83,742 327,191
    No. of positive specimens (%) 7,504 (9.0%) 17,271 (5.3%)
    Positive specimens by type
    Influenza A 7,422 (98.9%) 16,901 (97.9%)
    Influenza B 82 (1.1%) 370 (2.1%)

    View Chart Data | View Full Screen
    Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
    No. of specimens tested 8,187 33,638
    No. of positive specimens 467 1,699
    Positive specimens by type/subtype
    Influenza A 466 (99.8%) 1,674 (98.5%)
    (H1N1)pdm09 108 (33.8%) 289 (20.9%)
    H3N2 212 (66.3%) 1,097 (79.1%)
    H3N2v 0 0
    Subtyping not performed 146 288
    Influenza B 1 (0.2%) 25 (1.5%)
    Yamagata lineage 0 1 (6.3%)
    Victoria lineage 0 15 (93.8%)
    Lineage not performed 1 9


    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Public Health Novel Influenza A Virus


    A human infection with a novel influenza A virus was reported by the New Mexico Department of Health. The patient was infected with an influenza A(H3N2) variant (A(H3N2)v) virus. The illness occurred during the week ending October 15, 2022 (week 41). The patient is <18 years of age and is recovering from their illness. An investigation by local public health officials found that the patient had swine exposure prior to their illness onset. No person-to-person transmission of A(H3N2)v virus associated with this patient has been identified. The investigation is ongoing.

    A total of ten human infections with variant novel influenza A viruses have been reported in the United States in 2022, including five H3N2v (Michigan, New Mexico, West Virginia (3)) and five H1N2v (Georgia, Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

    Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Influenza Virus Characterization


    CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

    CDC genetically characterized 460 influenza viruses collected since May 1, 2022.
    A/H1 40
    6B.1A 40 (100%) 5a.1 5 (12.5%)
    5a.2 35 (87.5%)
    A/H3 418
    3C.2a1b 418 (100%) 1a 0
    1b 0
    2a 0
    2a.1 0
    2a.2 418 (100%)
    3C.3a 0 3a 0
    B/Victoria 2
    V1A 2 (100%) V1A 0
    V1A.1 0
    V1A.3 0
    V1A.3a 0
    V1A.3a.1 0
    V1A.3a.2 2 (100%)
    B/Yamagata 0
    Y3 0
    CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2022-2023 Northern Hemisphere recommended egg-based and cell- or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

    Influenza A Viruses
    • A (H1N1)pdm09: Twenty-six A(H1N1)pdm09 viruses were antigenically characterized by HI, and 24 (92%) were well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/588/2019-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines and 24 (92%) were well recognized by ferret antisera to egg-grown A/Victoria/2570/2019-like reference viruses representing the A(H1N1)pdm09 component for the egg-based influenza vaccines.
    • A (H3N2): Forty-two A(H3N2) viruses were antigenically characterized by HINT; all were well-recognized (reacting at titers that were within 8-fold of the homologous virus titer) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines and 40 (95%) were well-recognized by ferret antisera to egg-grown A/Darwin/9/2021-like reference viruses representing the A(H3N2) component for egg-based influenza vaccines.

    Influenza B Viruses
    • B/Victoria: One influenza B/Victoria-lineage virus was antigenically characterized by HI; it was well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines and by ferret antisera to egg-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the egg-based influenza vaccines.
    • B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

    Virus antiviral susceptibility data will be reported later this season when a sufficient number of specimens have been tested.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 43, 4.3% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This is an increase compared to week 42 and is above the national baseline of 2.5%. Regions 1, 2, 3, 4, 5, 6, 7, and 9 are above their region-specific baselines. The remaining two regions are below their region-specific baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data (current season only) | View Full Screen
    Outpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    The percentage of visits for respiratory illness reported in ILINet is increasing in all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years, and 65+ years).



    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 43
    (Week ending
    Oct. 29, 2022)
    Week 42
    (Week ending
    Oct. 22, 2022)
    Week 43
    (Week ending
    Oct. 29, 2022)
    Week 42
    (Week ending
    Oct. 22, 2022)
    Very High 11 1 42 9
    High 8 4 97 24
    Moderate 4 4 82 38
    Low 11 12 131 109
    Minimal 21 34 332 505
    Insufficient Data 0 0 245 244



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 43, 117 (0.8%) of 14,221 reporting LTCFs reported at least one influenza positive test among their residents.


    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 13 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

    A total of 842 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2022, and October 29, 2022; 95.0% were associated with influenza A virus, 3.6% were associated with influenza B virus, 0.5% with influenza A virus and influenza B virus co-infection, and 1.0% with influenza virus for which the type was not determined. Among 115 hospitalizations with influenza A subtype information, 26.1% were A(H1N1)pdm09 virus and 72.2% were A(H3N2).

    The overall cumulative hospitalization rate per 100,000 population was 2.9. This cumulative hospitalization rate is higher than the cumulative in-season hospitalization rate observed in week 43 during previous seasons going back to 2010-2011, which ranged from 0 to 0.5. The highest hospitalization rates per 100,000 population were among adults aged ≥ 65 years (6.3), followed by children aged 0-4 years (5.5), adults aged 50-64 (2.8), children aged 5-17 years (2.6), and adults aged 18-49 years (1.5).

    Cumulative hospitalization rates for each age group were higher than cumulative in-season hospitalization rates previously observed during week 43; since 2010-11, in-season rates ranged from 0 to 0.9 among children 0-4 years, 0 to 0.3 among children 5-17 years, 0 to 0.2 among adults 18-49 years, 0 to 0.5 among adults 50-64 years, and 0.1 to 1.4 among adults ≥ 65 years.



    View Full Screen

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 43, 4,326 patients with laboratory-confirmed influenza were admitted to a hospital.


    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on November 3, 2022, 9.1% of the deaths that occurred during the week ending October 29, 2022 (week 43), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 6.0% for this week. Among the 2,153 PIC deaths reported for this week, 988 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and 29 listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.

    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    Two influenza-associated pediatric deaths were reported to CDC during week 43. Both deaths were associated with influenza A(H3) viruses.

    One death occurred during week 43 (the week ending October 29, 2022). This was the second influenza-associated pediatric death occurring during the 2022-2023 season that has been reported to CDC.

    The other death occurred during week 37 (the week ending September 17, 2022), which was during the 2021-2022 season. The total number of pediatric deaths that occurred in the 2021-2022 season is 44.

    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied

    Weekly U.S. Influenza Surveillance Report

    Print
    Updated October 28, 2022

    Note: CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review.

    Key Updates for Week 42, ending October 22, 2022

    Early increases in seasonal influenza activity continue, with the southeast and south-central areas of the country reporting the highest levels of activity.
    Viruses


    Clinical Lab6.2%


    positive for influenza
    this week


    Public Health Lab
    The most frequently reported viruses this week were influenza A(H3N2).

    Virus Characterization
    Genetic and antigenic characterization are summarized in this report.
    Illness


    Outpatient Respiratory Illness3.3%


    of visits to a health care provider are for respiratory illness this week
    (above baseline)


    Outpatient Respiratory Illness: Activity Map
    This week, 1 jurisdiction experienced moderate activity and 13 jurisdictions experienced high or very high activity.

    Long-term Care Facilities0.5%


    of facilities reported
    ≥ 1 influenza-positive test
    among residents this week.

    Severe Disease


    FluSurv-NET1.5 per 100,000


    cumulative hospitalization rate

    HHS Protect Hospitalizations2,332


    patients admitted to hospitals with influenza
    this week.


    NCHS Mortality9.2%


    of deaths attributed to pneumonia, influenza, or COVID-19 this week (above threshold)

    Pediatric Deaths1


    influenza-associated death reported this week

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

    Key Points
    • Influenza activity continues to increase. Regions 4 (southeast) and 6 (south-central) are reporting the highest levels of flu activity.
    • The first influenza-associated pediatric death of the 2022-2023 season was reported this week.
    • CDC estimates that, so far this season, there have been at least 880,000 flu illnesses, 6,900 hospitalizations, and 360 deaths from flu.
    • The cumulative hospitalization rate in the FluSurv-NET system is higher than the rate observed in week 42 during previous seasons going back to 2010-2011.
    • An annual flu vaccine is the best way to protect against flu. Vaccination helps prevent infection and can also prevent serious outcomes in people who get vaccinated but still get sick with flu.
    • CDC recommends that everyone ages 6 months and older get a flu vaccine annually.
    • There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.
    U.S. Virologic Surveillance


    Nationally, the percentage of specimens testing positive for influenza in clinical laboratories is increasing; however, activity varies by region. Percent positivity increased ≥ 0.5% this week in regions 2, 3, 4, 5, 6, 7, 8, 9, and 10, and was similar to the previous week but trending upward in region 1. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 66,955 216,088
    No. of positive specimens (%) 4,129 (6.2%) 9,142 (4.2%)
    Positive specimens by type
    Influenza A 4,061 (98.4%) 8,887 (97.2%)
    Influenza B 68 (1.6%) 255 (2.8%)

    View Chart Data | View Full Screen
    Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
    No. of specimens tested 8,367 24,935
    No. of positive specimens 298 984
    Positive specimens by type/subtype
    Influenza A 291 (97.7%) 965 (98.1%)
    (H1N1)pdm09 43 (25.4%) 121 (16.3%)
    H3N2 126 (74.6%) 621 (83.7%)
    H3N2v 0 0
    Subtyping not performed 122 223
    Influenza B 7 (2.3%) 19 (1.9%)
    Yamagata lineage 0 0
    Victoria lineage 0 8 (100%)
    Lineage not performed 7 11


    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Influenza Virus Characterization


    CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

    CDC genetically characterized 452 influenza viruses collected since May 1, 2022.
    A/H1 38
    6B.1A 38 (100%) 5a.1 5 (13.2%)
    5a.2 33 (86.8%)
    A/H3 412
    3C.2a1b 412 (100%) 1a 0
    1b 0
    2a 0
    2a.1 0
    2a.2 412 (100%)
    3C.3a 0 3a 0
    B/Victoria 2
    V1A 2 (100%) V1A 0
    V1A.1 0
    V1A.3 0
    V1A.3a 0
    V1A.3a.1 0
    V1A.3a.2 2 (100%)
    B/Yamagata 0
    Y3 0
    CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2022-2023 Northern Hemisphere recommended egg-based and cell- or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

    Influenza A Viruses
    • A (H1N1)pdm09: Fourteen A(H1N1)pdm09 viruses were antigenically characterized by HI, and 12 (86%) were well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/588/2019-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines and 12 (86%) were well recognized by ferret antisera to egg-grown A/Victoria/2570/2019-like reference viruses representing the A(H1N1)pdm09 component for the egg-based influenza vaccines.
    • A (H3N2): Thirty-five A(H3N2) viruses were antigenically characterized by HINT; all were well-recognized (reacting at titers that were within 8-fold of the homologous virus titer) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines and 33 (94%) were well-recognized by ferret antisera to egg-grown A/Darwin/9/2021-like reference viruses representing the A(H3N2) component for egg-based influenza vaccines.

    Influenza B Viruses
    • B/Victoria: One influenza B/Victoria-lineage virus was antigenically characterized by HI; it was well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines and by ferret antisera to egg-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the egg-based influenza vaccines
    • B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

    Virus antiviral susceptibility data will be reported later this season when a sufficient number of specimens have been tested.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 42, 3.3% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This increased compared to week 41 and is above the national baseline of 2.5%. Regions 2, 3, 4, 5, 6, 7, and 9 are at or above their region-specific baselines. The remaining three regions are below their region-specific baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data (current season only) | View Full Screen
    Outpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    The percentage of visits for respiratory illness reported in ILINet is trending upwards in all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years, and 65+ years).



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 42
    (Week ending
    Oct. 22, 2022)
    Week 41
    (Week ending
    Oct. 15, 2022)
    Week 42
    (Week ending
    Oct. 22, 2022)
    Week 41
    (Week ending
    Oct. 15, 2022)
    Very High 2 1 13 9
    High 11 9 65 39
    Moderate 1 8 63 63
    Low 14 8 134 103
    Minimal 26 29 398 414
    Insufficient Data 1 0 256 301



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 42, 75 (0.5%) of 14,264 reporting LTCFs reported at least one influenza positive test among their residents.


    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 13 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. As data are received each week, prior case counts and rates are updated accordingly.

    A total of 443 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between October 1, 2022, and October 22, 2022; 94.4% were associated with influenza A virus, 3.4% were associated with influenza B virus, 0.5% with influenza A virus and influenza B virus co-infection, and 1.8% with influenza virus for which the type was not determined. Among 59 hospitalizations with influenza A subtype information, 27.1% were A(H1N1)pdm09 virus and 72.9% were A(H3N2).

    The overall cumulative hospitalization rate per 100,000 population was 1.5. This cumulative hospitalization rate is higher than the cumulative in-season hospitalization rate observed in week 42 during previous seasons going back to 2010-2011, which ranged from 0 to 0.3. The highest hospitalization rates per 100,000 population were among adults aged ≥ 65 years (3.0) and children aged 0-4 years (3.0), followed by children aged 5-17 years (1.7), adults aged 50-64 (1.3) and adults aged 18-49 years (0.8).

    Cumulative hospitalization rates for each age group were higher than cumulative in-season hospitalization rates previously observed during week 42; since 2010-11, in-season rates ranged from 0 to 0.4 among children 0-4 years, 0 to 0.1 among children 5-17 years, 0 to 0.2 among adults 18-49 years, 0 to 0.3 among adults 50-64 years, and 0 to 1.0 among adults ≥ 65 years.



    View Full Screen

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 42, 2,332 patients with laboratory-confirmed influenza were admitted to a hospital.


    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on October 27, 2022, 9.2% of the deaths that occurred during the week ending October 22, 2022 (week 42), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.9% for this week. Among the 2,128 PIC deaths reported for this week, 949 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and 15 listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.

    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    One influenza-associated pediatric death occurring during the 2022-2023 season was reported to CDC during week 42. The death was associated with an influenza A(H3) virus and occurred during week 40 (the week ending October 8, 2022). This is the first influenza-associated pediatric death occurring during the 2022-2023 season that has been reported to CDC.

    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report

    Print
    Updated October 21, 2022

    Note: CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review.

    Key Updates for Week 41, ending October 15, 2022

    Early increases in seasonal influenza activity have been reported in most of the United States, with the southeast and south-central areas of the country reporting the highest levels of activity.
    Viruses


    Clinical Lab4.4%


    positive for influenza
    this week


    Public Health Lab
    The most frequently reported viruses this week were influenza A(H3N2).

    Virus Characterization
    Genetic and antigenic characterization are summarized in this report.
    Illness


    Outpatient Respiratory Illness3.0%


    of visits to a health care provider are for respiratory illness this week
    (above baseline)


    Outpatient Respiratory Illness: Activity Map
    This week, 8 jurisdictions experienced moderate activity and 10 jurisdictions experienced high or very high activity.

    Long-term Care Facilities0.4%


    of facilities reported
    ≥ 1 influenza-positive test
    among residents this week.

    Severe Disease


    FluSurv-NET
    Hospitalization rates will be updated starting later this season.

    HHS Protect Hospitalizations1,674


    patients admitted to hospitals with influenza
    this week.


    NCHS Mortality8.8%


    of deaths attributed to pneumonia, influenza, or COVID-19 this week (above threshold)

    Pediatric Deaths0


    influenza-associated deaths reported this week

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

    Key Points
    • Influenza activity is increasing in most of the country. Regions 4 (southeast) and 6 (south-central) are reporting the highest levels of flu activity.
    • An annual flu vaccine is the best way to protect against flu. Vaccination helps prevent infection and can also prevent serious outcomes in people who get vaccinated but still get sick with flu.
    • CDC recommends that everyone ages 6 months and older get a flu vaccine, ideally by the end of October.
    • There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.
    U.S. Virologic Surveillance


    Nationally, the percentage of specimens testing positive for influenza in clinical laboratories is increasing; however, activity varies by region. Percent positivity increased ≥ 0.5% this week in regions 3, 4, 6, and 9, and was similar to or lower than the previous week in all other regions. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 61,813 134,628
    No. of positive specimens (%) 2,712 (4.4%) 4,782 (3.6%)
    Positive specimens by type
    Influenza A 2,639 (97.3%) 4,610 (96.4%)
    Influenza B 73 (2.7%) 172 (3.6%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
    No. of specimens tested 6,854 14,607
    No. of positive specimens 137 349
    Positive specimens by type/subtype
    Influenza A 135 (98.5%) 341 (97.7%)
    (H1N1)pdm09 20 (22.5%) 50 (20.5%)
    H3N2 69 (77.5%) 194 (79.5%)
    H3N2v 0 0
    Subtyping not performed 46 97
    Influenza B 2 (1.5%) 8 (2.3%)
    Yamagata lineage 0 0
    Victoria lineage 0 2 (100%)
    Lineage not performed 2 6



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    A human infection with a novel influenza A virus was reported by the Michigan Department of Health and Human Services. The patient was infected with an influenza A(H3N2) variant (A(H3N2)v) virus. The illness occurred during week 36 of 2022. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had indirect swine exposure at an agricultural fair prior to their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H3N2)v virus associated with this patient has been identified.

    A total of nine human infections with variant novel influenza A viruses have been reported in the United States in 2022, including four H3N2v (Michigan (1) West Virginia (3)) and five H1N2v (Georgia, Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

    Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

    Additional information regarding human infections with novel influenza A viruses:

    Surveillance Methods | FluView Interactive


    Influenza Virus Characterization


    CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

    CDC genetically characterized 446 influenza viruses collected since May 1, 2022.
    A/H1 36
    6B.1A 36 (100%) 5a.1 5 (13.9%)
    5a.2 31 (86.1%)
    A/H3 408
    3C.2a1b 408 (100%) 1a 0
    1b 0
    2a 0
    2a.1 0
    2a.2 408 (100%)
    3C.3a 0 3a 0
    B/Victoria 2
    V1A 2 (100%) V1A 0
    V1A.1 0
    V1A.3 0
    V1A.3a 0
    V1A.3a.1 0
    V1A.3a.2 2 (100%)
    B/Yamagata 0
    Y3 0
    CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2022-2023 Northern Hemisphere recommended egg-based and cell- or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

    Influenza A Viruses
    • A (H1N1)pdm09: Eleven A(H1N1)pdm09 viruses were antigenically characterized by HI, and 9 (82%) were well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/588/2019-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines and 9 (82%) were well recognized by ferret antisera to egg-grown A/Victoria/2570/2019-like reference viruses representing the A(H1N1)pdm09 component for the egg-based influenza vaccines.
    • A (H3N2): Thirty-two A(H3N2) viruses were antigenically characterized by HINT; all were well-recognized (reacting at titers that were within 8-fold of the homologous virus titer) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines and 30 (94%) were well-recognized by ferret antisera to egg-grown A/Darwin/9/2021-like reference viruses representing the A(H3N2) component for egg-based influenza vaccines.

    Influenza B Viruses
    • B/Victoria: One influenza B/Victoria-lineage virus was antigenically characterized by HI; it was well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the cell- and recombinant-based influenza vaccines and by ferret antisera to egg-grown B/Austria/1359417/2021-like reference viruses representing the B/Victoria component for the egg-based influenza vaccines
    • B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

    Virus antiviral susceptibility data will be reported later this season when a sufficient number of specimens have been tested.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 41, 3.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This increased compared to week 40 and is above the national baseline of 2.5%. Regions 2, 3, 4, and 6 are above their region-specific baselines, and regions 7 and 9 are at their respective baselines. The remaining four regions are below their region-specific baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    The percentage of visits for respiratory illness reported in ILINet is trending upwards in all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years, and 65+ years).



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 41
    (Week ending
    Oct. 15, 2022)
    Week 40
    (Week ending
    Oct. 8, 2022)
    Week 41
    (Week ending
    Oct. 15, 2022)
    Week 40
    (Week ending
    Oct. 8, 2022)
    Very High 1 1 9 9
    High 9 4 38 23
    Moderate 8 4 60 38
    Low 9 14 101 106
    Minimal 28 32 389 495
    Insufficient Data 0 0 332 258



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 41, 64 (0.4%) of 14,239 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in selected counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET estimated hospitalization rates will be updated weekly starting later this season.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 41, 1,674 patients with laboratory-confirmed influenza were admitted to a hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on October 20, 2022, 8.8% of the deaths that occurred during the week ending October 15, 2022 (week 41), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.8% for this week. Among the 2,060 PIC deaths reported for this week, 931 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and 18 listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.


    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    No influenza-associated pediatric deaths were reported to CDC during week 41. No influenza-associated pediatric deaths occurring during the 2022-2023 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report

    Print
    Updated October 14, 2022

    Note: CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review.

    Key Updates for Week 40, ending October 8, 2022

    Early increases in seasonal influenza activity have been reported in most of the United States, with the southeast and south-central areas of the country reporting the highest levels of activity.
    Viruses


    Clinical Lab3.3%


    positive for influenza
    this week


    Public Health Lab
    The most frequently reported viruses this week were influenza A(H3N2).

    Virus Characterization
    Influenza virus characterization information will be reported later this season.
    Illness


    Outpatient Respiratory Illness2.6%


    of visits to a health care provider are for respiratory illness this week
    (above baseline)


    Outpatient Respiratory Illness: Activity Map
    This week, 3 jurisdictions experienced moderate activity and 6 jurisdictions experienced high or very high activity.

    Long-term Care Facilities0.3%


    of facilities reported
    ≥ 1 influenza-positive test
    among residents this week.

    Severe Disease


    FluSurv-NET
    Hospitalization rates will be updated starting later this season.

    HHS Protect Hospitalizations1,322


    patients admitted to hospitals with influenza
    this week.


    NCHS Mortality8.7%


    of deaths attributed to pneumonia, influenza, or COVID-19 this week (above threshold)

    Pediatric Deaths3


    influenza-associated deaths reported this week; all occurred during the 2021-2022 season.

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.

    Key Points
    • This is the first FluView of the 2022-2023 influenza season.
    • Influenza activity is low but increasing in most of the country. Regions 4 (southeast) and 6 (south-central) are reporting the highest levels of flu activity.
    • An annual flu vaccine is the best way to protect against flu. Vaccination helps prevent infection and can also prevent serious outcomes in people who get vaccinated but still get sick with flu.
    • CDC recommends that everyone ages 6 months and older get a flu vaccine, ideally by the end of October.
    • There are also prescription flu antiviral drugs that can be used to treat flu illness; those need to be started as early as possible.
    U.S. Virologic Surveillance


    Nationally, the percentage of specimens testing positive for influenza in clinical laboratories is increasing; however, activity varies by region. Percent positivity increased this week in regions 3, 4, 6, 7, and 9, and was similar to or lower than the previous week in all other regions. For regional and state level data and age group distribution, please visit FluView Interactive. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 58,481 53,565
    No. of positive specimens (%) 1,274 (2.2%) 1,766 (3.3%)
    Positive specimens by type
    Influenza A 1,213 (95.2%) 1,686 (95.5%)
    Influenza B 61 (4.8%) 80 (4.5%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
    No. of specimens tested 7,729 7,261
    No. of positive specimens 133 83
    Positive specimens by type/subtype
    Influenza A 130 (97.7%) 81 (97.6%)
    (H1N1)pdm09 18 (26.9%) 16 (36.4%)
    H3N2 49 (73.1%) 28 (63.6%)
    H3N2v 0 0
    Subtyping not performed 63 37
    Influenza B 3 (2.3%) 2 (2.4%)
    Yamagata lineage 0 0
    Victoria lineage 1 (100%) 1 (100%)
    Lineage not performed 2 1



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Influenza Virus Characterization


    CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local public health laboratories according to the Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating influenza viruses are to the reference viruses representing viruses contained in the current influenza vaccines. The data are also used to monitor evolutionary changes that continually occur in influenza viruses circulating in humans. CDC also tests susceptibility of circulating influenza viruses to antiviral medications including the neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir.

    CDC has genetically characterized 396 influenza viruses collected since May 1, 2022. While there are little data to date, most of the H3N2 viruses so far are genetically closely related to the 2022-2023 Northern Hemisphere vaccine virus, but there are some antigenic differences that have developed as H3N2 viruses have continued to evolve.
    A/H1 21
    6B.1A 21 (100%) 5a.1 5 (23.8%)
    5a.2 16 (76.2%)
    A/H3 373
    3C.2a1b 373 (100%) 1a 0
    1b 0
    2a 0
    2a.1 0
    2a.2 373 (100%)
    3C.3a 0 3a 0
    B/Victoria 2
    V1A 2 (100%) V1A 0
    V1A.1 0
    V1A.3 0
    V1A.3a 0
    V1A.3a.1 0
    V1A.3a.2 2 (100%)
    B/Yamagata 0
    Y3 0
    CDC antigenically characterizes influenza viruses by hemagglutination inhibition (HI) (H1N1pdm09, B/Victoria, and B/Yamagata viruses) or neutralization-based HINT (H3N2 viruses) using antisera that ferrets make after being infected with reference viruses representing the 2022-2023 Northern Hemisphere recommended egg-based and cell- or recombinant-based vaccine viruses. Antigenic differences between viruses are determined by comparing how well the antibodies made against the vaccine reference viruses recognize the circulating viruses that have been grown in cell culture. Ferret antisera are useful because antibodies raised against a particular virus can often recognize small changes in the surface proteins of other viruses. In HI assays, viruses with similar antigenic properties have antibody titer differences of less than or equal to 4-fold when compared to the reference (vaccine) virus. In HINT, viruses with similar antigenic properties have antibody neutralization titer differences of less than 8-fold. Viruses selected for antigenic characterization are a subset representing the genetic changes in the surface proteins seen in genetically characterized viruses.

    Influenza A Viruses
    • A (H1N1)pdm09: Two A(H1N1)pdm09 viruses were antigenically characterized by HI, and none were well recognized (reacting at titers that were within 4-fold of the homologous virus titer) by ferret antisera to cell-grown A/Wisconsin/588/2019-like reference viruses representing the A(H1N1)pdm09 component for the cell- and recombinant-based influenza vaccines or by ferret antisera to egg-grown A/Victoria/2570/2019-like reference viruses representing the A(H1N1)pdm09 component for the egg-based influenza vaccines.
    • A (H3N2): Twenty-four A(H3N2) viruses were antigenically characterized by HINT; all were well-recognized (reacting at titers that were within 8-fold of the homologous virus titer) by ferret antisera to cell-grown A/Darwin/6/2021-like reference viruses representing the A(H3N2) component for the cell- and recombinant-based influenza vaccines and 22 (92%) were well-recognized by ferret antisera to egg-grown A/Darwin/9/2021-like reference viruses representing the A(H3N2) component for egg-based influenza vaccines.

    Influenza B Viruses
    • B/Victoria: No influenza B/Victoria-lineage viruses were antigenically characterized by HI.
    • B/Yamagata: No influenza B/Yamagata-lineage viruses were available for antigenic characterization.

    Virus antiviral susceptibility data will be reported later this season when a sufficient number of specimens have been tested.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for respiratory illness referred to as influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 40, 2.6% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. This increased compared to week 39 and is above the national baseline of 2.5%. Eight of the 10 HHS regions are below their region-specific baselines; regions 3 and 4 are above their respective baselines. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    The percentage of visits for respiratory illness reported in ILINet is trending upward in all age groups (0-4 years, 5-24 years, 25-49 years, 50-64 years, and 65+ years).



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 40
    (Week ending
    Oct. 8, 2022)
    Week 39
    (Week ending
    Oct. 1, 2022)
    Week 40
    (Week ending
    Oct. 8, 2022)
    Week 39
    (Week ending
    Oct. 1, 2022)
    Very High 1 0 7 4
    High 5 4 24 25
    Moderate 3 2 36 36
    Low 14 11 106 92
    Minimal 32 38 490 507
    Insufficient Data 0 0 266 265



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 40, 41 (0.3%) of 14,331 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in selected counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET estimated hospitalization rates will be updated weekly starting later this season.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 40, 1,322 patients with laboratory-confirmed influenza were admitted to a hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on October 13, 2022, 8.7% of the deaths that occurred during the week ending October 8, 2022 (week 40), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.8% for this week. Among the 1,928 PIC deaths reported for this week, 898 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and nine listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.


    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    Three influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 40. The deaths were associated with influenza A (H3) viruses and occurred during weeks 5, 16, and 21 of 2022 (weeks ending February 5, April 23, and May 28 respectively).

    A total of 43 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC. No influenza-associated pediatric deaths occurring during the 2022-2023 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report

    Print
    Updated October 7, 2022

    2021-2022 Influenza Season for Week 39, ending October 1, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 40,709 3,801,185
    No. of positive specimens (%) 1,021 (2.5%) 137,999 (3.6%)
    Positive specimens by type
    Influenza A 969 (94.9%) 135,571 (98.2%)
    Influenza B 52 (5.1%) 2,428 (1.8%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 7,379 1,123,222
    No. of positive specimens 49 26,322
    Positive specimens by type/subtype
    Influenza A 47 (95.9%) 26,156 (99.4%)
    (H1N1)pdm09 7 (24.1%) 86 (0.4%)
    H3N2 22 (75.9%) 20,712 (99.6%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 18 5,354
    Influenza B 2 (4.1%) 166 (0.6%)
    Yamagata lineage 0 1 (2.2%)
    Victoria lineage 0 45 (97.8%)
    Lineage not performed 2 120



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 39, 2.4% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 39, the percentage of visits for respiratory illness reported in ILINet was 9.6% among those 0-4 years, 3.6% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 39
    (Week ending
    Oct. 1, 2022)
    Week 38
    (Week ending
    Sep. 24, 2022)
    Week 39
    (Week ending
    Oct. 1, 2022)
    Week 38
    (Week ending
    Sep. 24, 2022)
    Very High 0 0 3 5
    High 4 4 25 13
    Moderate 3 1 35 29
    Low 11 11 92 90
    Minimal 37 39 487 527
    Insufficient Data 0 0 287 265



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 39, 36 (0.3%) of 14,367 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 39, 885 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on October 6, 2022, 8.7% of the deaths that occurred during the week ending October 1, 2022 (week 39), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.7% for this week. Among the 2,035 PIC deaths reported for this week, 983 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and five listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 39. The death was associated with an influenza A virus for which no subtyping was performed and occurred during week 12 (the week ending March 26, 2022).

    A total of 40 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied

    Weekly U.S. Influenza Surveillance Report

    Print
    Updated September 30, 2022

    2021-2022 Influenza Season for Week 38, ending September 24, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 50,292 3,743,239
    No. of positive specimens (%) 677 (1.3%) 136,829 (3.7%)
    Positive specimens by type
    Influenza A 628 (92.8%) 134,464 (98.3%)
    Influenza B 49 (7.2%) 2,365 (1.7%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 9,907 1,115,302
    No. of positive specimens 52 26,181
    Positive specimens by type/subtype
    Influenza A 47 (90.4%) 26,020 (99.4%)
    (H1N1)pdm09 12 (36.4%) 75 (0.4%)
    H3N2 21 (63.6%) 20,591 (99.6%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 14 5,350
    Influenza B 5 (9.6%) 161 (0.6%)
    Yamagata lineage 0 1 (2.3%)
    Victoria lineage 0 43 (97.7%)
    Lineage not performed 5 117



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 38, 2.2% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 38, the percentage of visits for respiratory illness reported in ILINet was 9.0% among those 0-4 years, 3.5% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 38
    (Week ending
    Sep. 24, 2022)
    Week 37
    (Week ending
    Sep. 17, 2022)
    Week 38
    (Week ending
    Sep. 24, 2022)
    Week 37
    (Week ending
    Sep. 17, 2022)
    Very High 0 0 4 3
    High 3 2 13 8
    Moderate 2 2 29 24
    Low 9 5 85 73
    Minimal 40 46 520 555
    Insufficient Data 1 0 278 266



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 38, 31 (0.2%) of 14,528 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 38, 739 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on September 29, 2022, 8.7% of the deaths that occurred during the week ending September 24, 2022 (week 38), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.6% for this week. Among the 2,035 PIC deaths reported for this week, 1,014 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and six listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    Two influenza-associated pediatric deaths occurring in weeks 30 (the week ending July 30, 2022) and 33 (the week ending August 20, 2022) of the 2021-2022 season were reported to CDC during week 38. Both deaths were associated with influenza A viruses for which no subtyping was performed.

    A total of 39 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated September 23, 2022

    2021-2022 Influenza Season for Week 37, ending September 17, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 47,546 3,676,988
    No. of positive specimens (%) 378 (0.8%) 135,983 (3.7%)
    Positive specimens by type
    Influenza A 353 (93.4%) 133,676 (98.3%)
    Influenza B 25 (6.6%) 2,307 (1.7%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 10,436 1,104,730
    No. of positive specimens 35 26,062
    Positive specimens by type/subtype
    Influenza A 31 (88.6%) 25,907 (99.4%)
    (H1N1)pdm09 2 (9.1%) 62 (0.3%)
    H3N2 20 (90.9%) 20,517 (99.7%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 9 5,324
    Influenza B 4 (11.4%) 155 (0.6%)
    Yamagata lineage 0 1 (2.3%)
    Victoria lineage 0 43 (97.7%)
    Lineage not performed 4 111



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    A human infection with a novel influenza A virus was reported by the Georgia Department of Public Health. The patient was infected with an influenza A(H1N2) variant (A(H1N2)v) virus. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had swine contact and had attended agricultural fairs prior to their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified.

    A total of eight human infections with variant novel influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and five H1N2v (Georgia, Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

    Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

    Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 37, 2.0% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 37, the percentage of visits for respiratory illness reported in ILINet was 8.1% among those 0-4 years, 3.2% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.5% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 37
    (Week ending
    Sep. 17, 2022)
    Week 36
    (Week ending
    Sep. 10, 2022)
    Week 37
    (Week ending
    Sep. 17, 2022)
    Week 36
    (Week ending
    Sep. 10, 2022)
    Very High 1 0 3 5
    High 1 2 9 6
    Moderate 3 3 24 32
    Low 3 4 71 72
    Minimal 47 46 546 545
    Insufficient Data 0 0 276 269



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 37, 32 (0.2%) of 14,515 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 37, 637 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on September 22, 2022, 9.2% of the deaths that occurred during the week ending September 17, 2022 (week 37), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.6% for this week. Among the 2,058 PIC deaths reported for this week, 1,055 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and four listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    Two influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 37. One death was associated with an influenza B virus with no lineage determined and occurred during week 15 (the week ending April 16, 2022). The other death was associated with an influenza A(H3) virus and occurred during week 21 (the week ending May 28, 2022).

    A total of 37 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated September 16, 2022

    2021-2022 Influenza Season for Week 36, ending September 10, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 40,698 3,612,434
    No. of positive specimens (%) 279 (0.7%) 135,450 (3.7%)
    Positive specimens by type
    Influenza A 263 (94.3%) 133,178 (98.3%)
    Influenza B 16 (5.7%) 2,272 (1.7%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 10,145 1,093,878
    No. of positive specimens 38 25,990
    Positive specimens by type/subtype
    Influenza A 38 (100%) 25,839 (99.4%)
    (H1N1)pdm09 4 (14.8%) 56 (0.3%)
    H3N2 23 (85.2%) 20,464 (99.7%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 11 5,315
    Influenza B 0 (0%) 151 (0.6%)
    Yamagata lineage 0 1 (2.3%)
    Victoria lineage 0 43 (97.7%)
    Lineage not performed 0 107



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    Two human infections with a novel influenza A virus were reported during week 36 (Michigan and Wisconsin). Both patients were infected with influenza A(H1N2) variant (A(H1N2)v) viruses.

    The Michigan Department of Health and Human Services reported one infection in a patient <18 years of age. The patient was not hospitalized and has recovered from their illness. An investigation by local public health officials found that the patient had attended an agricultural fair prior to their illness onset. Additional investigation identified one household contact who had respiratory illness. This contact attended the same agricultural fair and became ill at the same time as the patient. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified.

    The Wisconsin Department of Health reported one infection in a patient < 18 years of age. An investigation by local public health officials is ongoing.

    A total of seven human infections with variant novel influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and four H1N2v (Michigan, Ohio, Oregon, Wisconsin) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person. Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken.

    Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

    Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 36, 1.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 36, the percentage of visits for respiratory illness reported in ILINet was 7.8% among those 0-4 years, 3.1% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 36

    (Week ending
    Sep. 10, 2022)
    Week 35

    (Week ending
    Sep. 3, 2022)
    Week 36

    (Week ending
    Sep. 10, 2022)
    Week 35

    (Week ending
    Sep. 3, 2022)
    Very High 0 0 4 5
    High 2 3 6 10
    Moderate 3 2 32 24
    Low 4 1 70 65
    Minimal 45 47 528 554
    Insufficient Data 1 2 289 271



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 36, 23 (0.2%) of 14,563 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 36, 577 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on September 15, 2022, 9.2% of the deaths that occurred during the week ending September 10, 2022 (week 36), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,055 PIC deaths reported for this week, 1,052 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and five listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 36. The death was associated with an influenza A(H3) virus and occurred during week 20 (the week ending May 21, 2022).

    A total of 35 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated September 9, 2022

    2021-2022 Influenza Season for Week 35, ending September 3, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 42,261 3,547,791
    No. of positive specimens (%) 247 (0.6%) 135,046 (3.8%)
    Positive specimens by type
    Influenza A 228 (92.3%) 132,809 (98.3%)
    Influenza B 19 (7.7%) 2,237 (1.7%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 10,106 1,082,187
    No. of positive specimens 18 25,893
    Positive specimens by type/subtype
    Influenza A 15 (83.3%) 25,743 (99.4%)
    (H1N1)pdm09 4 (50.0%) 46 (0.2%)
    H3N2 4 (50.0%) 20,385 (99.8%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 7 5,308
    Influenza B 3 (16.7%) 150 (0.6%)
    Yamagata lineage 0 1 (2.3%)
    Victoria lineage 0 42 (97.7%)
    Lineage not performed 3 107



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 35, 1.9% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 35, the percentage of visits for respiratory illness reported in ILINet was 7.2% among those 0-4 years, 3.0% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 35
    (Week ending
    Sep. 3, 2022)
    Week 34
    (Week ending
    Aug. 27, 2022)
    Week 35
    (Week ending
    Sep. 3, 2022)
    Week 34
    (Week ending
    Aug. 27, 2022)
    Very High 0 0 3 4
    High 3 1 8 10
    Moderate 2 3 25 20
    Low 2 2 60 74
    Minimal 45 48 524 542
    Insufficient Data 3 1 309 279



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 35, 28 (0.2%) of 14,481 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 35, 509 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on September 8, 2022, 9.6% of the deaths that occurred during the week ending September 3, 2022 (week 35), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 1,769 PIC deaths reported for this week, 963 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and seven listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    No influenza-associated pediatric deaths occurring during the 2021-2022 season were reported to CDC during week 35.

    A total of 34 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated September 2, 2022

    2021-2022 Influenza Season for Week 34, ending August 27, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 41,365 3,491,587
    No. of positive specimens (%) 209 (0.5%) 134,683 (3.9%)
    Positive specimens by type
    Influenza A 182 (87.1%) 132,473 (98.4%)
    Influenza B 27 (12.9%) 2,210 (1.6%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 10,805 1,071,312
    No. of positive specimens 40 25,775
    Positive specimens by type/subtype
    Influenza A 39 (97.5%) 25,628 (99.4%)
    (H1N1)pdm09 5 (17.9%) 39 (0.2%)
    H3N2 23 (82.1%) 20,307 (99.8%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 11 5,278
    Influenza B 1 (2.5%) 147 (0.6%)
    Yamagata lineage 0 1 (2.3%)
    Victoria lineage 1 (100%) 42 (97.7%)
    Lineage not performed 0 104



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 34, 1.8% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 34, the percentage of visits for respiratory illness reported in ILINet was 7.0% among those 0-4 years, 2.9% among those 5-24 years, 1.1% among those 25-49 years, 0.7% among those 50-64 years, and 0.6% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 34
    (Week ending
    Aug. 27, 2022)
    Week 33
    (Week ending
    Aug. 20, 2022)
    Week 34
    (Week ending
    Aug. 27, 2022)
    Week 33
    (Week ending
    Aug. 20, 2022)
    Very High 0 0 3 2
    High 1 1 10 6
    Moderate 3 1 18 21
    Low 2 2 74 56
    Minimal 47 51 537 574
    Insufficient Data 2 0 287 270



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 34, 28 (0.2%) of 14,510 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 34, 486 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on September 1, 2022, 9.2% of the deaths that occurred during the week ending August 27, 2022 (week 34), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,117 PIC deaths reported for this week, 1,120 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and eight listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    One influenza-associated pediatric death occurring during the 2021-2022 season was reported to CDC during week 34. The death was associated with an influenza A virus for which no subtyping was performed and occurred during week 29 (the week ending July 23, 2022).

    A total of 34 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated August 26, 2022

    2021-2022 Influenza Season for Week 33, ending August 20, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 32,491 3,431,123
    No. of positive specimens (%) 159 (0.5%) 134,375 (3.9%)
    Positive specimens by type
    Influenza A 136 (85.5%) 132,205 (98.4%)
    Influenza B 23 (14.5%) 2,170 (1.6%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 11,062 1,059,682
    No. of positive specimens 39 25,703
    Positive specimens by type/subtype
    Influenza A 37 (94.9%) 25,557 (99.4%)
    (H1N1)pdm09 1 (3.4%) 28 (0.1%)
    H3N2 28 (96.6%) 20,237 (99.9%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 8 5,288
    Influenza B 2 (5.1%) 146 (0.6%)
    Yamagata lineage 0 1 (2.4%)
    Victoria lineage 1 (100%) 41 (97.6%)
    Lineage not performed 1 104



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    A human infection with a novel influenza A virus was reported by the Ohio Department of Health. The patient was infected with a swine-origin influenza A(H1N2) variant (A(H1N2)v) virus. The patient is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials found that the patient had attended an agricultural fair on the day of their illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person transmission of A(H1N2)v virus associated with this patient has been identified. This is the second patient infected with an H1N2v virus reported in the United States in 2022.

    A total of five human infections with variant influenza A viruses have been reported in the United States in 2022, including three H3N2v (West Virginia) and two H1N2v (Ohio, Oregon) viruses. When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant” influenza virus. Most human infections with variant influenza viruses occur following exposure to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm.

    Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 33, 1.5% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 33, the percentage of visits for respiratory illness reported in ILINet was 6.3% among those 0-4 years, 2.4% among those 5-24 years, 1.0% among those 25-49 years, 0.8% among those 50-64 years, and 0.6% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 33
    (Week ending
    Aug. 20, 2022)
    Week 32
    (Week ending
    Aug. 13, 2022)
    Week 33
    (Week ending
    Aug. 20, 2022)
    Week 32
    (Week ending
    Aug. 13, 2022)
    Very High 0 0 1 2
    High 1 0 6 5
    Moderate 2 0 20 15
    Low 1 3 56 36
    Minimal 51 52 568 587
    Insufficient Data 0 0 278 284



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 33, 31 (0.2%) of 14,575 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 33, 477 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on August 25, 2022, 10.0% of the deaths that occurred during the week ending August 20, 2022 (week 33), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,320 PIC deaths reported for this week, 1,268 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and seven listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 33.

    A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated August 19, 2022

    2021-2022 Influenza Season for Week 32, ending August 13, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 41,657 3,385,846
    No. of positive specimens (%) 165 (0.4%) 134,111 (4.0%)
    Positive specimens by type
    Influenza A 147 (89.1%) 131,975 (98.4%)
    Influenza B 18 (10.9%) 2,136 (1.6%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 11,925 1,019,489
    No. of positive specimens 27 25,565
    Positive specimens by type/subtype
    Influenza A 25 (92.6%) 25,421 (99.4%)
    (H1N1)pdm09 0 26 (0.1%)
    H3N2 20 (100%) 20,130 (99.9%)
    H3N2v 0 4 (<0.1%)
    Subtyping not performed 5 5,261
    Influenza B 2 (7.4%) 144 (0.6%)
    Yamagata lineage 0 1 (2.4%)
    Victoria lineage 0 40 (97.6%)
    Lineage not performed 2 103



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    A human infection with a novel influenza A virus was reported by the Oregon Health Authority. The patient was infected with an influenza A(H1N2) variant (A(H1N2)v) virus. The patients is <18 years of age, was not hospitalized, and has recovered from their illness. An investigation by local public health officials did not identify contact with swine or agricultural fair attendance by the patient prior to illness onset. Additional investigation did not identify respiratory illness in any of the patient’s household contacts. No person-to-person spread of this virus has been confirmed to date associated with this case. This is the first patient infected with an H1N2v virus reported in the United States in 2022.

    A total of four human infections with a variant influenza A virus have been reported in the United States in 2022, including three H3N2v (West Virginia) and one H1N2v (Oregon).

    When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following close proximity to swine, but human-to-human transmission can occur. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood, and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm. Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 32, 1.4% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 32, the percentage of visits for respiratory illness reported in ILINet was 5.9% among those 0-4 years, 2.0% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.7% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 32
    (Week ending
    Aug. 13, 2022)
    Week 31
    (Week ending
    Aug. 6, 2022)
    Week 32
    (Week ending
    Aug. 13, 2022)
    Week 31
    (Week ending
    Aug. 6, 2022)
    Very High 0 0 1 1
    High 0 0 5 4
    Moderate 0 1 14 10
    Low 3 1 35 54
    Minimal 51 53 581 588
    Insufficient Data 1 0 293 272



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 32, 39 (0.3%) of 14,576 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During week 32, 457 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    Based on NCHS mortality surveillance data available on August 18, 2022, 9.9% of the deaths that occurred during the week ending August 13, 2022 (week 32), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,165 PIC deaths reported for this week, 1,192 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and six listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 32.

    A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:


  • Lance
    replied
    Weekly U.S. Influenza Surveillance Report


    Updated August 12, 2022

    2021-2022 Influenza Season for Week 31, ending August 6, 2022

    All data are preliminary and may change as more reports are received.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    Additional information on the current and previous influenza seasons for each surveillance component are available on FluView Interactive.
    U.S. Virologic Surveillance

    Clinical Laboratories


    The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories (the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is increasing or decreasing.

    No. of specimens tested 34,645 3,308,468
    No. of positive specimens (%) 153 (0.4%) 133,801 (4.0%)
    Positive specimens by type
    Influenza A 138 (90.2%) 131,699 (98.4%)
    Influenza B 15 (9.8%) 2,102 (1.6%)

    View Chart Data | View Full Screen Public Health Laboratories


    The results of tests performed by public health laboratories nationwide are summarized below. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Data from public health laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage. Viruses known to be associated with recent live attenuated influenza vaccine (LAIV) receipt or found upon further testing to be a vaccine virus are not included, as they are not circulating influenza viruses.
    No. of specimens tested 12,394 1,006,839
    No. of positive specimens 25 25,507
    Positive specimens by type/subtype
    Influenza A 23 (92.0%) 25,365 (99.4%)
    (H1N1)pdm09 0 26 (0.1%)
    H3N2 15 (83.3%) 20,092 (99.9%)
    H3N2v 3 (16.7) 4 (<0.1%)
    Subtyping not performed 5 5,243
    Influenza B 2 (8.0%) 142 (0.6%)
    Yamagata lineage 0 1 (2.4%)
    Victoria lineage 0 40 (97.6%)
    Lineage not performed 2 101



    View Chart Data | View Full Screen

    Additional virologic surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
    Novel Influenza A Virus


    Two human infections with a novel influenza A virus were reported by West Virginia. The patients were infected with an influenza A(H3N2) variant (A(H3N2)v) virus. Both patients are <18 years of age, were not hospitalized, and have recovered from their illness. An investigation by health officials showed that both patients attended an agricultural fair and that swine at this fair tested positive for swine influenza A(H3N2). No person-to-person spread of this virus has been confirmed to date. This is the third patient infected with an H3N2v virus reported from West Virginia in the past 2 weeks; all three attended the same agricultural fair prior to illness onset.

    When an influenza virus that normally circulates in swine (but not people) is detected in a person, it is called a “variant influenza virus.” Most human infections with variant influenza viruses occur following close proximity to swine, but human-to-human transmission has occurred previously. It is important to note that in most cases, variant influenza viruses have not shown the ability to spread easily and sustainably from person to person.

    Early identification and investigation of human infections with novel influenza A viruses are critical so that the risk of infection can be understood and appropriate public health measures can be taken. Additional information on influenza in swine, variant influenza virus infection in humans, and guidance to interact safely with swine can be found at www.cdc.gov/flu/swineflu/index.htm. Additional information regarding human infections with novel influenza A viruses can be found at http://gis.cdc.gov/grasp/fluview/Novel_Influenza.html.
    Outpatient Respiratory Illness Surveillance


    The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) monitors outpatient visits for influenza-like illness [ILI (fever plus cough or sore throat)], not laboratory-confirmed influenza, and will therefore capture respiratory illness visits due to infection with any pathogen that can present with similar symptoms, including influenza, SARS-CoV-2, and RSV. Due to the COVID-19 pandemic, health care-seeking behaviors have changed, and people may be accessing the health care system in alternative settings not captured as a part of ILINet or at a different point in their illness than they might have before the pandemic. Therefore, it is important to evaluate syndromic surveillance data, including that from ILINet, in the context of other sources of surveillance data to obtain a complete and accurate picture of influenza, SARS-CoV-2, and other respiratory virus activity. CDC is tracking the COVID-19 pandemic in a weekly publication called COVID Data Tracker Weekly Review. Information about other respiratory virus activity can be found on CDC’s National Respiratory and Enteric Virus Surveillance System (NREVSS) website.
    Outpatient Respiratory Illness Visits


    Nationwide during week 31, 1.5% of patient visits reported through ILINet were due to respiratory illness that included fever plus a cough or sore throat, also referred to as ILI. Multiple respiratory viruses are co-circulating, and the relative contribution of influenza virus infection to ILI varies by location.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”


    View Chart Data (current season only) | View Full ScreenOutpatient Respiratory Illness Visits by Age Group


    More than 70% of ILINet participants provide both the number of patient visits for respiratory illness and the total number of patient visits for the week broken out by age group. Data from this subset of providers are used to calculate the percentages of patient visits for respiratory illness by age group.

    During week 31, the percentage of visits for respiratory illness reported in ILINet was 6.1% among those 0-4 years, 1.9% among those 5-24 years, 1.1% among those 25-49 years, 0.8% among those 50-64 years, and 0.7% among those 65 years and older.



    * Effective October 3, 2021 (week 40), the ILI definition (fever plus cough or sore throat) no longer includes “without a known cause other than influenza.”

    View Chart Data | View Full Screen
    Outpatient Respiratory Illness Activity Map


    Data collected in ILINet are used to produce a measure of ILI activity* by state/jurisdiction and Core Based Statistical Areas (CBSA).
    Week 31
    (Week ending
    Aug. 6, 2022)
    Week 30
    (Week ending
    Jul. 30, 2022)
    Week 31
    (Week ending
    Aug. 6, 2022)
    Week 30
    (Week ending
    Jul. 30, 2022)
    Very High 0 0 0 2
    High 0 0 4 7
    Moderate 1 2 10 18
    Low 1 1 53 48
    Minimal 53 52 582 570
    Insufficient Data 0 0 280 284



    *Data collected in ILINet may disproportionally represent certain populations within a jurisdiction or CBSA, and therefore, may not accurately depict the full picture of influenza activity for the entire jurisdiction or CBSA. Differences in the data presented here by CDC and independently by some health departments likely represent differing levels of data completeness with data presented by the health department likely being the more complete.

    Additional information about medically attended visits for ILI for current and past seasons:
    Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
    Long-term Care Facility (LTCF) Surveillance


    LTCFs (e.g., nursing homes/skilled nursing, long-term care for the developmentally disabled, and assisted living facilities) from all 50 states and U.S. territories report data on influenza virus infections among residents through the National Healthcare Safety Network (NHSN) Long-term Care Facility Component. During week 31, 40 (0.3%) of 14,636 reporting LTCFs reported at least one influenza positive test among their residents.



    View Chart Data | View Full Screen

    Additional information about long-term care facility surveillance:
    Surveillance Methods | Additional Data
    Hospitalization Surveillance

    FluSurv-NET


    The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in select counties in 14 states and represents approximately 9% of the U.S. population. FluSurv-NET hospitalization data are preliminary. Patients admitted for laboratory-confirmed influenza-related hospitalization after June 11, 2022, will not be included in FluSurv-NET for the 2021-2022 season. Data on patients admitted through June 11, 2022, will continue to be updated as additional information is received.

    Additional FluSurv-NET hospitalization surveillance information for current and past seasons and additional age groups:
    Surveillance Methods |FluView Interactive: Rates by Age, Sex, and Race/Ethnicity or Data on Patient Characteristics
    HHS Protect Hospitalization Surveillance


    Hospitals report to HHS Protect the number of patients admitted with laboratory-confirmed influenza. During 31, 506 patients with laboratory-confirmed influenza were admitted to the hospital.



    View Chart Data | View Full Screen

    Additional HHS Protect hospitalization surveillance information:
    Surveillance Methods | Additional Data
    Mortality Surveillance

    National Center for Health Statistics (NCHS) Mortality Surveillance


    On June 6, 2022, the National Vital Statistics System (NVSS) cause of death coding system began a system-wide upgrade, which required a temporary suspension of routine NVSS surveillance reporting. The upgrade required all 2022 death records to be reprocessed into the system. As routine NVSS surveillance reporting resumes, users may temporarily observe lower death counts for prior weeks in 2022 as the backlog is reprocessed and reloaded into the system.

    Based on NCHS mortality surveillance data available on August 11, 2022, 10.0% of the deaths that occurred during the week ending August 6, 2022 (week 31), were due to pneumonia, influenza, and/or COVID-19 (PIC). This percentage is above the epidemic threshold of 5.5% for this week. Among the 2,226 PIC deaths reported for this week, 1,207 had COVID-19 listed as an underlying or contributing cause of death on the death certificate, and 4 listed influenza, indicating that current PIC mortality is due primarily to COVID-19 and not influenza. The data presented are preliminary and may change as more data are received and processed.



    View Chart Data | View Full Screen

    Additional pneumonia, influenza and COVID-19 mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive
    Influenza-Associated Pediatric Mortality


    No influenza-associated pediatric death occurring during the 2021-2022 season were reported to CDC during week 31.

    A total of 33 influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.


    View Full Screen

    Additional pediatric mortality surveillance information for current and past seasons:
    Surveillance Methods | FluView Interactive


    Additional National and International Influenza Surveillance Information


    FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics.

    National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-related workplace absenteeism among full-time workers in the United States are available from NIOSH.

    U.S. State and local influenza surveillance: Select a jurisdiction below to access the latest local influenza information. World Health Organization:
    Additional influenza surveillance information from participating WHO member nations is available through
    FluNet and the Global Epidemiology Reports.

    WHO Collaborating Centers for Influenza:
    Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia)

    Europe:
    The most up-to-date influenza information from Europe is available from WHO/Europe and the European Centre for Disease Prevention and Control.

    Public Health Agency of Canada:
    The most up-to-date influenza information from Canada is available in Canada’s weekly FluWatch report.

    Public Health England:
    The most up-to-date influenza information from the United Kingdom is available from Public Health England.

    Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

    A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component is available on the surveillance methods page.

    https://www.cdc.gov/flu/weekly/index.htm

    Leave a comment:

Working...
X